台股 » 個股 » 訊聯 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

訊聯

(1784)
可現股當沖
  • 股價
    65.5
  • 漲跌
    ▼0.8
  • 漲幅
    -1.21%
  • 成交量
    288
  • 產業
    上櫃 生技醫療類股
  • 105人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
訊聯 (1784)籌碼相關-華南永昌-豐原 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

華南永昌-豐原 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/05/020.567.50168.0066.50-0.5380-0.13%
2024/04/30165.00164.4064.2003620.00%
2024/04/262.567.61269.5066.400.53550.14%
2024/04/24564.66363.0063.1022910.69%
2023/09/2800.00766.6166.50-7950-0.74%
2023/09/27567.3600.0066.7059560.52%
2023/09/26267.1000.0067.1029620.21%
2023/09/2200.00161.4061.70-1980-0.10%
2023/09/2000.00563.5062.60-51,041-0.48%
2023/09/1900.00164.6064.10-11,103-0.09%
2023/09/14165.9000.0065.1011,1110.09%
2023/08/3100.00163.7063.30-11,154-0.09%
2023/08/30165.3000.0064.3011,1570.09%
2023/08/18268.6000.0068.7021,2450.16%
2023/08/14366.2000.0066.2031,3210.23%
2023/08/0800.00872.1072.80-81,442-0.55%
2023/07/3100.00267.4066.40-21,614-0.12%
2023/07/28164.0000.0064.0011,6800.06%
2023/07/21165.0000.0065.2011,8590.05%
2023/07/1900.00366.4765.70-32,032-0.15%
2023/07/18366.9000.0066.6032,0430.15%
2023/07/1400.00166.5067.80-12,053-0.05%
2023/07/13163.8000.0063.8012,0650.05%
2023/07/121064.5000.0064.40102,1030.48%
2023/06/28465.80464.5066.5002,2790.00%
2023/05/2600.00162.8061.90-12,156-0.05%
2023/05/22569.4000.0068.4052,0940.24%
2023/05/1700.000.467.1466.30-0.42,198-0.02%
2023/05/113.268.0200.0066.103.21,9850.16%
2023/05/101.272.49673.6773.40-4.81,897-0.26%
2023/05/09269.5000.0067.8021,8340.11%
2023/05/08171.40171.9072.0001,8210.00%
2023/05/05368.9000.0070.0031,7800.17%
2023/05/04169.5000.0069.5011,7180.06%
2023/04/24157.00161.4059.4001,3210.00%
2023/04/2100.00156.7055.90-11,209-0.08%
2023/04/19156.1000.0056.7011,0770.09%
2023/04/1400.00552.4052.70-5961-0.52%
2023/04/1300.00352.8752.50-3931-0.32%
2023/04/0600.00547.2046.65-5791-0.63%
2023/03/31546.80146.9046.9547800.51%
2023/03/30646.8800.0046.7067690.78%
2023/03/07545.14545.1045.1007770.00%
2023/02/15248.85148.2547.9015270.19%
訊聯細胞智藥攜手韓新創公司 搶攻外泌體商機Anue鉅亨-2023/11/27
〈訊聯展望〉看好基因定序健保商機 脊髓肌肉萎縮檢測滲透率上看90%Anue鉅亨-2023/08/09
訊聯 相關文章
訊聯 相關影音